A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
10.3904/kjim.2015.30.5.620
- Author:
Ji Hyun LEE
1
;
Sung Gyun AHN
;
Bonil PARK
;
Sang Wook PARK
;
Yong Seok KANG
;
Jun Won LEE
;
Young Jin YOUN
;
Min Soo AHN
;
Jang Young KIM
;
Byung Su YOO
;
Seung Hwan LEE
;
Junghan YOON
Author Information
1. Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea. sgahn@yonsei.ac.kr
- Publication Type:Comparative Study ; Original Article
- Keywords:
Prasugrel;
Ticagrelor;
Platelet function test
- MeSH:
Acute Coronary Syndrome/blood/diagnosis/ethnology/*therapy;
Adenosine/administration & dosage/adverse effects/*analogs & derivatives/pharmacology;
Aged;
*Asian Continental Ancestry Group;
Blood Platelets/*drug effects/metabolism;
Drug Administration Schedule;
Drug Monitoring/methods;
European Continental Ancestry Group;
Female;
Hemorrhage/chemically induced;
Humans;
Male;
Middle Aged;
*Percutaneous Coronary Intervention/adverse effects;
Pilot Projects;
Platelet Aggregation Inhibitors/administration & dosage/adverse effects;
Platelet Function Tests;
Prasugrel Hydrochloride/administration & dosage/adverse effects/*pharmacology;
Purinergic P2Y Receptor Antagonists/administration & dosage/adverse effects/*pharmacology;
Receptors, Purinergic P2Y12/blood/*drug effects;
Republic of Korea;
Retrospective Studies;
Risk Factors;
Time Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2015;30(5):620-628
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Newer P2Y12 inhibitors, such as prasugrel and ticagrelor, have greater antiplatelet efficacy but may increase the risk of bleeding. In this study, we compared the pharmacodynamic efficacy of prasugrel and ticagrelor in East Asian patients with acute coronary syndrome (ACS). METHODS: We selected 83 ACS patients undergoing percutaneous coronary intervention who were discharged with 90 mg ticagrelor twice daily (n = 24), 10 mg prasugrel daily (n = 39) or 5 mg prasugrel daily (n = 20). After 2 to 4 weeks, on-treatment platelet reactivity (OPR) was assessed in terms of P2Y12 reaction units (PRUs) using the VerifyNow P2Y12 assay (Accumetrics). We compared East Asian (85 < PRU < or = 275) and Caucasian (85 < PRU < or = 208) criteria for assessing the therapeutic window of OPR. RESULTS: OPR was lowest in the ticagrelor group, followed by the 10 mg prasugrel and 5 mg prasugrel groups (49.1 ± 29.9 vs. 83.7 ± 57.1 vs. 168.5 ± 60.8, respectively; p < 0.001). The 5 mg prasugrel group had the highest proportion of patients with OPR values within the therapeutic window, followed by the 10 mg prasugrel and ticagrelor groups (90.0% vs. 46.2% vs. 12.5%, respectively; p < 0.001 for East Asian criteria; 60.0% vs. 43.6% vs. 12.5%, respectively; p < 0.001 for Caucasian criteria). CONCLUSIONS: Short-term administration of 5 mg prasugrel facilitated maintenance within the therapeutic window of OPR compared with the 10 mg prasugrel and ticagrelor groups. Thus, 5 mg prasugrel daily may be the optimal antiplatelet regimen for stabilized East Asian ACS patients.
